Clinical Trial Update: Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib mesylate plus camrelizumab with transarterial chemoembolization as neoadjuvant therapy for hepatocellular carcinoma is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Wei Zhang | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING